Metastatic Non-Small Cell Lung Cancer
7 competing products in clinical development for Metastatic Non-Small Cell Lung Cancer.
Pipeline by Phase
Phase 22
Phase 35
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Dato-DXd + Osimertinib + Pemetrexed + Carboplatin + Cisplatin | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Datopotamab Deruxtecan + Pembrolizumab | Daiichi Sankyo | Phase 3 | Recruiting | 47 |
| Ramucirumab + Placebo + Erlotinib + Gefitinib + Osimertinib | Eli Lilly | Phase 3 | Active | 44 |
| Datopotamab Deruxtecan + Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin | Daiichi Sankyo | Phase 3 | Active | 44 |
| Pembrolizumab + Lenvatinib + Docetaxel | Eisai | Phase 3 | Completed | 40 |
| CS7017 tablets + Paclitaxel + Carboplatin + Placebo Tablets | Daiichi Sankyo | Phase 2 | Completed | 35 |
| Sotorasib + Lenvatinib | Eisai | Phase 2 | Withdrawn | 27 |